A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

NCT05215067 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: AK104
DRUG: Docetaxel

Sponsor

Akeso